Free Trial
NYSEAMERICAN:AZTR

Azitra 11/12/2024 Earnings Report

Azitra logo
$0.81 +0.01 (+1.50%)
Closing price 09/12/2025 04:10 PM Eastern
Extended Trading
$0.81 -0.01 (-0.62%)
As of 09/12/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Azitra EPS Results

Actual EPS
-$1.13
Consensus EPS
-$3.20
Beat/Miss
Beat by +$2.06
One Year Ago EPS
N/A

Azitra Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Azitra Announcement Details

Quarter
Time
After Market Closes
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Azitra's next earnings date is estimated for Tuesday, November 11, 2025, based on past reporting schedules.

Conference Call Resources

Azitra Earnings Headlines

Azitra Inc Modifies Agreement with Alumni Capital
College grad makes $64,000 a month
A Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took dozens of technology and finance experts, including one PhD astrophysicist, and $4 million in total research costs). In a multi-year backtest, this breakthrough beat stocks, bonds, gold... even Warren Buffett.tc pixel
Why Is Azitra (AZTR) Stock Soaring Today
See More Azitra Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Azitra? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Azitra and other key companies, straight to your email.

About Azitra

Azitra (NYSEAMERICAN:AZTR) Inc is a clinical-stage biopharmaceutical company focused on developing live bacterial therapies for dermatological conditions. Headquartered in Cambridge, Massachusetts, the company leverages its proprietary ActoBiotic platform to formulate topical treatments that aim to modulate the skin’s native microbial ecosystem.

The company’s lead investigational therapies are being evaluated in early-phase clinical studies for inflammatory skin disorders, including atopic dermatitis and other conditions characterized by microbial imbalance. By delivering live commensal organisms directly to affected skin regions, Azitra seeks to restore healthy barrier function and reduce inflammation without relying on conventional small-molecule or biologic drug approaches.

Founded in 2018, Azitra is traded on the NYSE American under the symbol AZTR. Its research and development operations combine microbiology, formulation science and translational dermatology, and the company’s clinical trials are conducted primarily in North America. Azitra has pursued collaborations with academic and medical centers to support its pipeline advancement.

Azitra’s leadership team brings together expertise in microbiome research, dermatology and pharmaceutical development, guiding the company toward regulatory milestones and strategic partnerships. With a mission to harness the therapeutic potential of the skin microbiome, Azitra aims to offer novel, targeted treatments for patients with chronic skin diseases.

View Azitra Profile

More Earnings Resources from MarketBeat